Targeting Phosphatidylserine in Anti-Cancer Therapy

Title: Targeting Phosphatidylserine in Anti-Cancer Therapy

Volume: 15 Issue: 23

Author(s): Heidi Kenis and Chris Reutelingsperger

Affiliation:

Abstract: Targeted delivery of cytotoxic agents limits the severe toxic side-effects of anti-cancer drugs on healthy tissues. Annexin A5 is a well explored probe to target phosphatidylserine (PS)-expressing cells in vivo. Our novel understanding of the cellular and molecular mechanism of annexin A5 as a cell-entry agent and the finding that PS is expressed on living tumour as well as endothelial cells in the tumour vasculature, will allow the development of lead compounds for anticancer therapy.

Cite this article as:

Kenis Heidi and Reutelingsperger Chris, Targeting Phosphatidylserine in Anti-Cancer Therapy, Current Pharmaceutical Design 2009; 15 (23) . https://dx.doi.org/10.2174/138161209788923903